Rosiglitazone protects against severe hemorrhagic shock-induced organ damage in rats

Medical Science Monitor

Volumn 17, Issue 10, 2011, Pages

  Yang, Fwu Lin ^a,b   Subeq, Yi Maun ^a   Lee, Chung Jen ^c   Lee, Ru Ping ^a   Peng, Tai Chu ^c   Harn, Horng Jyh ^d   Hsu, Bang Gee ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemokine; Cytokine; Hemorrhagic shock; Rats; Rosiglitazone

Indexed keywords

AUTACOID; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DRUG EFFICACY; EXPERIMENTAL MODEL; FLUID RESUSCITATION; GLUCOSE BLOOD LEVEL; HEART RATE; HEMORRHAGIC SHOCK; HISTOPATHOLOGY; INTESTINE INJURY; KIDNEY INJURY; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; LUNG INJURY; MALE; MEAN ARTERIAL PRESSURE; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SURVIVAL RATE; TACHYCARDIA; UREA NITROGEN BLOOD LEVEL;

EID: 80054021011     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881975     Document Type: Article

References (37)

1. Keel M, Trentz O: Pathophysiology of polytrauma. Injury, 2005; 36: 691-709
2. Angele MK, Schneider CP, Chaudry IH: Bench-to-bedside review: latest results in hemorrhagic shock. Crit Care, 2008; 12: 218
3. Frink M, Hsieh YC, Thobe BM et al: TLR4 regulates Kupffer cell che-mokine production, systemic infammation and lung neutrophil infl-tration following trauma-hemorrhage. Mol Immunol, 2007; 44: 2625-30
4. Duan SZ, Usher MG, Mortensen RM: Peroxisome proliferator-activat-ed receptor-gamma-mediated effects in the vasculature. Circ Res, 2008; 102: 283-94
5. Yki-Järvinen H: Thiazolidinediones. N Engl J Med, 2004; 351: 1106-18
6. Mohanty P, Aljada A, Ghanim H et al: Evidence for a potent antiin-fammatory effect of rosiglitazone. J Clin Endocrinol Metab, 2004; 89: 2728-35
7. Wu WT, Lee CC, Lee CJ et al: Rosiglitazone ameliorates endotoxin induced organ damage in conscious rats. Biol Res Nurs, 2011; 13(1): 38-43
8. Haveman JW, Muller Kobold AC, Tervaert JW et al: The central role of monocytes in the pathogenesis of sepsis: consequences for immuno-monitoring and treatment. Neth J Med, 1999; 55: 132-41
9. Lee CC, Lee RP, Subeq YM et al: Fluvastatin attenuates severe hemor-rhagic shock-induced organ damage in rats. Resuscitation, 2009; 80: 372-78
10. Lee CJ, Lee RP, Subeq YM et al: Propofol protects hemorrhagic shock-induced organ damage in conscious spontaneously hypertension rats. Biol Res Nurs, 2009; 11: 152-62
11. Wu WT, Lin NT, Subeq YM et al: Erythropoietin protects severe hem-orrhagic shock-induced organ damage in conscious rats. Injury, 2010; 41: 818-24
12. Cuzzocrea S, Pisano B, Dugo L et al: Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reper-fusion injury of the gut. Br J Pharmacol, 2003; 140: 366-76
13. Wiest R, Rath HC: Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol, 2003; 17: 397-425
14. Baregamian N, Mourot JM, Ballard AR et al: PPAR-gamma agonist protects against intestinal injury during necrotizing enterocolitis. Biochem Biophys Res Commun, 2009; 379: 423-27
15. Senthil M, Watkins A, Barlos D et al: Intravenous injection of trauma-hemorrhagic shock mesenteric lymph causes lung injury that is dependent upon activation of the inducible nitric oxide synthase pathway. Ann Surg, 2007; 246: 822-30
16. Chima RS, Hake PW, Piraino G et al: Ciglitazone ameliorates lung in-fammation by modulating the inhibitor kappaB protein kinase/nu-clear factor-kappaB pathway after hemorrhagic shock. Crit Care Med, 2008; 36: 2849-57
17. Mao Z, Ong AC: Peroxisome proliferator-activated receptor gamma agonists in kidney disease - future promise, present fears. Nephron Clin Pract, 2009; 112: c230-41
18. Collin M, Abdelrahman M, Thiemermann C: Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. Eur J Pharmacol, 2004; 486: 233-35
19. Celiński K, Madro A, Prozorow-Król B et al: Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma)-specifc agonist, as a modulator in experimental acute pancreatitis. Med Sci Monit, 2009; 15(1): BR21-29
20. Abdelrahman M, Collin M, Thiemermann C: The peroxisome prolifer-ator-activated receptor-gamma ligand 15-deoxyDelta12,14 prostaglan-din J2 reduces the organ injury in hemorrhagic shock. Shock, 2004; 22: 555-61
21. Rixen D, Siegel JH: Bench-to-bedside review: oxygen debt and its metabolic correlates as quantifers of the severity of hemorrhagic and post-traumatic shock. Crit Care, 2005; 9: 441-53
22. Luft FC: Lactic acidosis update for critical care clinicians. J Am Soc Nephrol, 2001; 12(Suppl.17): S15-19
23. Besler C, Doerries C, Giannotti G et al: Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev Cardiovasc Ther, 2008; 6: 1071-82
24. Bahrami S, Yao YM, Leichtfried G et al: Signifcance of TNF in hemorrhage-related hemodynamic alterations, organ injury, and mortality in rats. Am J Physiol, 1997; 272 (5-2): H2219-26
25. Brundage SI, Zautke NA, Holcomb JB et al: Interleukin-6 infusion blunts proinfammatory cytokine production without causing systematic tox-icity in a swine model of uncontrolled hemorrhagic shock. J Trauma, 2004; 57: 970-77
26. Schober A: Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol, 2008; 28: 1950-59
27. Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattrac-tant protein-1 (MCP-1): an overview. J Interferon Cytokine Res, 2009; 29: 313-26
28. Hsieh CH, Frink M, Hsieh YC et al: The role of MIP-1 alpha in the development of systemic infammatory response and organ injury following trauma hemorrhage. J Immunol, 2008; 181: 2806-12
29. Mizock BA: Alterations in fuel metabolism in critical illness: hypergly-caemia. Best Pract Res Clin Endocrinol Metab, 2001; 15: 533-51
30. McCowen KC, Malhotra A, Bistrian BR: Stress-induced hyperglycemia. Crit Care Clin, 2001; 17: 107-24
31. Fahy BG, Sheehy AM, Coursin DB: Glucose control in the intensive care unit. Crit Care Med, 2009; 37: 1769-76
32. Ajjan RA, Grant PJ: The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf, 2008; 7: 367-76
33. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al: Risk of acute myo-cardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010; 304: 411-18
34. Nissen SE, Wolski K: Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med, 2010; [Epub ahead of print]
35. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007; 356: 2457-71
36. Lenz A, Franklin GA, Cheadle WG: Systemic infammation after trauma. Injury, 2007; 38: 1336-45
37. Jeschke MG, Klein D, Herndon DN: Insulin treatment improves the systemic infammatory reaction to severe trauma. Ann Surg, 2004; 239: 553-60